Find Paid Research Studies in Avondale,Arizona

Browse Locations ... United States» ... Arizona» ... Avondale

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Conditions: Asthma; Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting - verified May 2013
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 1)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013
Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations

Condition: Colorectal Cancer
Intervention: Behavioral: Tailored navigation
Sponsors: Arizona State University; Arizona State University; Ohio State University; Mayo Clinic
Recruiting - verified May 2013
Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: GFF MDI (PT003); Drug: GP MDI (PT001); Drug: FF MDI (PT005); Drug: Placebo
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Conditions: Low-grade Serous Ovarian Cancer; Low-grade Serous Fallopian Tube Cancer; Low-grade Serous Peritoneal Cancer
Interventions: Drug: MEK162, MEK inhibitor; oral; Drug: Physician's choice chemotherapy
Sponsors: Array BioPharma; Array BioPharma
Not yet recruiting - verified May 2013
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers

Condition: Cancer
Intervention: Drug: SNX-5422
Sponsors: Esanex Inc.; Esanex Inc.
Recruiting - verified May 2013
Histological Characterization of Vaginal Cuff Tissue Using Different Energy Sources During Robotic Hysterectomy

Condition: Extent of Thermal Injury Using Different Energy Sources at the Time of Robotic Hysterectomy Procedure
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
A Study Of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: MPDL3280A
Sponsors: Genentech; Genentech
Not yet recruiting - verified May 2013
Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

Condition: Generalized Anxiety Disorder
Interventions: Drug: Placebo; Drug: Vilazodone
Sponsors: Forest Laboratories; Forest Laboratories
Not yet recruiting - verified April 2013
Study to Evaluate Safety & Efficacy of WC3011 in Postmenopausal Women With Dyspareunia

Condition: Vulvovaginal Atrophy
Interventions: Drug: Estradiol Vaginal Gel; Drug: Vehicle
Sponsors: Warner Chilcott; Warner Chilcott
Recruiting - verified April 2013
The Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Condition: Hepatic Encephalopathy
Interventions: Drug: Placebo; Drug: Rifaximin
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified April 2013
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Conditions: Multiple Sclerosis; Spasticity
Intervention: Drug: arbaclofen
Sponsors: Osmotica Pharmaceutical Corporation; Osmotica Pharmaceutical Corporation
Recruiting - verified April 2013
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

Condition: Major Depressive Disorder
Intervention: Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Not yet recruiting - verified April 2013
The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy

Conditions: Hepatic Encephalopathy; Cirrhosis
Interventions: Drug: Rifaximin; Drug: Rifaximin and Lactulose
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified April 2013
12 Week Efficacy and Safety Trial Followed by a 4 Week Withdrawal Period for Patients With Chronic Idiopathic Constipation

Condition: Chronic Idiopathic Constipation
Interventions: Drug: Elobixibat 10 mg; Drug: Elobixibat 5 mg; Drug: Placebo
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified May 2013
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification

Condition: Breast Cancer
Intervention:
Sponsors: Provista Diagnostics, Inc; Provista Diagnostics, Inc
Recruiting - verified April 2013
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

Condition: Chronic Idiopathic Constipation
Interventions: Drug: Elobixibat 10 mg; Drug: Elobixibat 5 mg; Drug: Placebo
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified May 2013
A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcers
Interventions: Device: Electrohydraulic-generated shock wave; Device: Sham device plus standard of care
Sponsors: SANUWAVE, Inc.; SANUWAVE, Inc.
Recruiting - verified May 2013
A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma

Condition: Asthma
Interventions: Drug: Placebo; Drug: JNJ-38518168
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Not yet recruiting - verified May 2013
Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Conditions: HIV; HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Conditions: Oncology; BRCA Mutated; High Grade Serous Ovarian Cancer; BRCA Mutated Breast Cancer
Intervention: Drug: Veliparib
Sponsors: AbbVie; AbbVie
Recruiting - verified May 2013
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Umeclidinium/vilanterol; Drug: Fluticasone propionate/salmeterol; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy

Condition: Hypogonadism
Interventions: Drug: Testosterone Solution; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2013
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcers
Interventions: Drug: DSC127; Drug: placebo vehicle gel
Sponsors: Derma Sciences, Inc.; Derma Sciences, Inc.; Integrium
Recruiting - verified April 2013
Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix

Conditions: Obesity; Diet Therapy; Diabetes Type 2
Intervention: Behavioral: Controlling Gestational Weight Gain
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2012
SynapDx Autism Gene Expression Analysis Study (STORY)

Condition: Autism
Intervention:
Sponsors: SynapDx; SynapDx
Recruiting - verified May 2013
SoundBite Hearing System 24 Month Multi Site Patient Use Study

Conditions: Single Sided Deafness; Conductive Hearing Loss
Intervention: Device: SoundBite Hearing System
Sponsors: Sonitus Medical Inc; Sonitus Medical Inc
Recruiting - verified May 2013
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: idarubicin; Drug: vorinostat; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Edoxaban in Peripheral Arterial Disease

Condition: Peripheral Arterial Disease
Interventions: Drug: edoxaban; Drug: Clopidogrel; Drug: Aspirin
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; UMC Utrecht
Recruiting - verified March 2013
Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: RO5452802; Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Condition: Spasticity
Intervention: Drug: Baclofen
Sponsors: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries Limited
Recruiting - verified April 2013
Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer

Conditions: Pancreatic Carcinoma Non-resectable; Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: nab-Paclitaxel
Sponsors: Western Regional Medical Center; Western Regional Medical Center
Recruiting - verified May 2013
Mechanical Debridement Verus Radiofrequency-Based Debridement to Treat Articular Cartilage Lesions With Partial Meniscectomy in the Knee (ACT)

Condition: Chondral Lesion Plus Partial Medial Meniscectomy
Interventions: Device: Mechanical Debridement (Mechanical Shaver); Device: Radiofrequency-Based Debridement
Sponsors: ArthroCare Corporation; ArthroCare Corporation
Recruiting - verified April 2013
A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

Conditions: Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Diffuse Large B-cell Lymphoma; Indolent Non-Hodgkin's Lymphoma
Intervention: Drug: GS-9973
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013
A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Human Insulin NPH
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Drug: Hydrocodone bitartrate extended-release tablets; Drug: Matching placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

Conditions: Primary Myelofibrosis; Post Polycythemia Vera Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
Sponsors: Mount Sinai School of Medicine; John Mascarenhas; Myeloproliferative Disorders-Research Consortium; National Cancer Institute (NCI); Incyte Corporation; Novartis
Recruiting - verified April 2013
A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Necitumumab; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat (BAY 63-2521)
Sponsors: Bayer; Bayer
Available - verified April 2013
Efficacy and Tolerability of BAF312 in Patients With Polymyositis

Condition: Polymyositis
Interventions: Drug: Placebo; Drug: BAF312
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

Condition: Kidney Transplantation
Interventions: Drug: ASKP1240; Drug: Tacrolimus; Drug: Mycophenolate Mofetil (MMF); Drug: Basiliximab; Drug: Corticosteroids
Sponsors: Astellas Pharma Inc; Astellas Pharma Global Development, Inc.; Kyowa Hakko Kirin Company, Limited
Recruiting - verified April 2013
Safety, Efficacy and Pharmacokinetics of ALD403

Condition: Migraine
Intervention: Biological: ALD403
Sponsors: Alder Biopharmaceuticals, Inc.; Alder Biopharmaceuticals, Inc.
Recruiting - verified April 2013
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Umeclidinium bromide 62.5mcg; Drug: Umeclidinium bromide 125mcg; Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Simtuzumab (GS-6624); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Placebo; Drug: Dulaglutide; Drug: Glimepiride
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer

Condition: Squamous Non Small Cell Lung Cancer
Interventions: Drug: Necitumumab; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)

Conditions: ST Segment Elevation Myocardial Infarction (STEMI); Allogeneic Mesenchymal Bone Marrow Cells
Intervention: Biological: ALLOGENEIC MESENCHYMAL BONE MARROW CELLS
Sponsors: Stemedica Cell Technologies, Inc.; Stemedica Cell Technologies, Inc.; Mercy Gilbert Medical Center at AZ; Chandler Regional Medical Center at Chandler AZ; University of California, San Diego
Not yet recruiting - verified January 2013
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Condition: Type 2 Diabetes
Interventions: Drug: lixisenatide (AVE0010); Drug: insulin glulisine (HMR1964)
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

Conditions: Amnestic Mild Cognitive Impairment; Alzheimer's Disease
Interventions: Drug: Insulin (Humulin® R U-100); Drug: Placebo
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS)
Not yet recruiting - verified May 2013
Long-Term Safety Of PF-00547659 In Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: PF-00547659; Drug: PF-00547659
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
LDL-C Assessment w/ PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally); Drug: Statin therapy
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Drug: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally)
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial

Condition: Aneurysm
Interventions: Drug: Doxycycline; Drug: Placebo
Sponsors: University of Maryland; University of Maryland; National Institute on Aging (NIA)
Recruiting - verified May 2013
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Conditions: Inflammation; Crohn's Disease
Interventions: Drug: NNC0114-0006; Drug: NNC0114-0006
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis

Condition: Knee Osteoarthritis
Interventions: Device: Durolane; Device: PBS
Sponsors: Q-Med AB; Q-Med AB
Recruiting - verified May 2013
A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing

Condition: Epidermolysis Bullosa
Interventions: Biological: ABH001; Other: Control wound treatment
Sponsors: Shire Regenerative Medicine, Inc.; Shire Regenerative Medicine, Inc.
Recruiting - verified April 2013
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer

Condition: Cancer
Interventions: Drug: Part 1 Cohort 1: Dabrafenib plus Panitumumab; Drug: Part 1 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab; Drug: Part 1 Cohort 3A: Dabrafenib plus Trametinib plus Panitumumab; Drug: Part 1 Cohort 3B: Dabrafenib plus Trametinib plus Panitumumab; Drug: Part 1 Cohort 4: Dabrafenib plus Trametinib plus Panitumumab; Drug: Part 2 Cohort 1: Dabrafenib plus Panitumumab; Drug: Part 2 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab; Drug: Part 3 Cohort 1: Dabrafenib plus Panitumumab; Drug: Part 3 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab; Drug: Part 3 Cohort 3: 5-fluorouracil-based chemotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: Treosulfan
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; medac GmbH
Not yet recruiting - verified May 2013
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

Condition: Advanced Idiopathic Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Placebo
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified April 2013
Early Diagnosis of Pulmonary Nodules

Conditions: Precancerous Conditions; Carcinoma
Intervention:
Sponsors: Integrated Diagnostics; Integrated Diagnostics
Recruiting - verified April 2013
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Condition: Alzheimer's Disease
Interventions: Drug: MK-8931; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: ELND005; Drug: Placebo
Sponsors: Elan Pharmaceuticals; Elan Pharma International Limited; Elan Pharmaceuticals
Recruiting - verified May 2013
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' BoostrixTM Vaccine in Previously Boosted Young Adults

Conditions: Diphtheria; Pertussis; Tetanus
Intervention: Biological: Boostrix
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

Conditions: Anemia; Primary Myelofibrosis; Secondary Myelofibrosis
Interventions: Drug: ruxolitinib phosphate; Drug: danazol
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2013
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

Conditions: Iron Deficiency; Iron Deficiency Anemia
Intervention: Drug: Ferric Citrate
Sponsors: Keryx Biopharmaceuticals; Keryx Biopharmaceuticals
Recruiting - verified May 2013
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Conditions: Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event
Interventions: Drug: Dapagliflozin 10 mg; Drug: Placebo tablet
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization
Recruiting - verified May 2013
Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

Conditions: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease
Interventions: Drug: Inhaled nitric oxide; Other: Placebo
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified April 2013
Maternal and Neurodevelopmental Outcomes of in Utero Antiepileptic Drug (AED) Exposure

Conditions: Epilepsy; Pregnancy
Intervention:
Sponsors: Emory University; Emory University; The EMMES Corporation
Recruiting - verified April 2013
A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies

Condition: Cancer
Interventions: Drug: GSK1120212B (Standard DMSO content); Drug: GSK1120212B (Lower DMSO content)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: AIR001 (sodium nitrite inhalation solution)
Sponsors: Aires Pharmaceuticals, Inc.; Aires Pharmaceuticals, Inc.
Recruiting - verified May 2013
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: AIR001
Sponsors: Aires Pharmaceuticals, Inc.; Aires Pharmaceuticals, Inc.
Recruiting - verified May 2013
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

Condition: Irritable Bowel Syndrome Characterized by Constipation
Interventions: Drug: Plecanatide; Drug: Placebo
Sponsors: Synergy Pharmaceuticals, Inc.; Synergy Pharmaceuticals, Inc.
Recruiting - verified May 2013
A Study of LY2940680 in Small Cell Lung Cancer

Condition: Small Cell Lung Carcinoma
Interventions: Drug: LY2940680; Drug: Carboplatin; Drug: Etoposide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Moderate to Severe Rheumatoid Arthritis Study

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study in Moderate to Severe Rheumatoid Arthritis Participants

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Conditions: Diabetes Mellitus, Type 2; Hyperglycemia
Interventions: Drug: Empagliflozin low dose qd; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose qd; Drug: Empagliflozin low dose bid; Drug: Metformin 500 mg bid; Drug: Empagliflozin high dose bid; Drug: Empagliflozin low dose bid; Drug: Metformin 1000 mg bid; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013
Barostim HOPE4HF (Hope for Heart Failure) Study

Condition: Heart Failure
Intervention: Device: Barostim Neo system
Sponsors: CVRx, Inc.; CVRx, Inc.
Recruiting - verified April 2013
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)

Condition: Hypercholesterolemia
Interventions: Drug: Anacetrapib 100 mg; Drug: Placebo for anacetrapib 100 mg; Drug: Anacetrapib 25 mg; Drug: Placebo for anacetrapib 25 mg
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients

Condition: Neutropenia
Interventions: Drug: HM10460A (45 μg/kg); Drug: HM10460A (135 μg/kg); Drug: HM10460A (270 μg/kg); Drug: Pegfilgrastim 6mg
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013
CARTO® 3 System and Real Time Intracardiac Ultrasound

Conditions: Atrial Fibrillation; Paroxysmal AF
Intervention: Device: Catheter Ablation
Sponsors: Biosense Webster, Inc.; Biosense Webster, Inc.
Recruiting - verified February 2013
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Condition: Alzheimer's Disease
Interventions: Drug: PF-05212377 (SAM-760); Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: Baricitinib; Drug: Methotrexate; Drug: Placebo; Drug: Folic Acid
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study in Moderate to Severe Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Adalimumab; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Condition: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions: Drug: GRT6005 Low-Dose Range; Drug: GRT6005 High-Dose Range; Drug: Placebo; Drug: Oxycodone CR
Sponsors: Forest Laboratories; Forest Laboratories; Grünenthal GmbH
Recruiting - verified May 2013
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: CK-2017357; Other: Placebo tablets
Sponsors: Cytokinetics; Cytokinetics
Recruiting - verified May 2013
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)

Condition: Hodgkin Disease
Intervention: Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Condition: Non-small Cell Lung Cancer(NSCLC)
Interventions: Drug: AT13387; Drug: Crizotinib
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified April 2013
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

Condition: Cystic Fibrosis
Intervention: Drug: ivacaftor
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis Foundation
Recruiting - verified April 2013
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

Condition: Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2013
A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome

Condition: Long QT Syndrome
Intervention:
Sponsors: Pediatrix Medical Group; Pediatrix Medical Group
Recruiting - verified May 2013
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age

Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).; Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine.; Biological: Varivax® (Merck & Co., Inc.); Biological: Havrix®; Biological: Prevnar 13® (Pfizer Inc.)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain

Condition: Neuropathic Pain
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

Conditions: Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Nonseasonal
Interventions: Biological: MK-8237 tablets; Biological: Placebo tablets; Drug: Rescue Medication: Self-Injectable Epinephrine; Drug: Rescue Medication: Loratadine tablets; Drug: Rescue Medication: Olopatadine ophthalmic drops; Drug: Rescue Medication: Mometasone furoate nasal spray
Sponsors: Merck; Merck
Recruiting - verified May 2013
Maternal Uterine Artery Doppler Study

Conditions: Pregnant Women; Greater Than or Equal to 18 Weeks Gestation; Uterine Artery Doppler
Intervention: Other: Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.
Sponsors: Obstetrix Medical Group; Obstetrix Medical Group
Recruiting - verified May 2013
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+ Metastatic Breast Cancer

Condition: Hormone Receptor Positive Breast Cancer
Interventions: Drug: Everolimus; Drug: Letrozole; Drug: Exemestane; Drug: Dexamethasone mouth rinse
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Condition: Multiple Sclerosis (MS)
Interventions: Drug: Laquinimod 0.6 mg; Drug: Matching Placebo; Drug: Laquinimod 1.2 mg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Peginterferon alfa-2b; Drug: Ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified April 2013
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium; Drug: Placebo matching Olodaterol; Drug: Tiotropium; Drug: Olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Condition: Malignant Melanoma
Intervention: Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Condition: Gastric Cancer
Interventions: Drug: Rilotumumab; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

Condition: Cystic Fibrosis
Interventions: Biological: KB001-A; Biological: Placebo Comparator
Sponsors: KaloBios Pharmaceuticals; KaloBios Pharmaceuticals
Recruiting - verified May 2013
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Biological: AMG 181; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures

Condition: Chronic Anal Fissures
Interventions: Drug: VEN 307; Drug: Placebo
Sponsors: Ventrus Biosciences, Inc; Ventrus Biosciences, Inc
Recruiting - verified May 2013
A Study of Evacetrapib in High-Risk Vascular Disease

Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; The Cleveland Clinic
Recruiting - verified May 2013
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection

Condition: Hepatitis C Virus
Interventions: Drug: ABT-450/r; Drug: ABT-267; Drug: Ribavirin
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: MK-3102 Placebo; Drug: Glimepiride; Drug: Glimepiride Placebo; Drug: Metformin; Drug: Insulin Glargine
Sponsors: Merck; Merck
Recruiting - verified April 2013
Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty

Condition: Postoperative Pain
Interventions: Drug: EXPAREL; Drug: Placebo
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc
Recruiting - verified May 2013
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

Condition: Diabetic Kidney Disease
Interventions: Drug: baricitinib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Incyte Corporation
Recruiting - verified May 2013
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Bilogicals measles, mumps and rubella vaccine live (GSK 209762).; Biological: Merck & Co., Inc.'s M-M-R®II, combined measles-mumps-rubella virus vaccine live.; Biological: Varivax® (Merck & Co., Inc.); Biological: Havrix®; Biological: Prevnar 13® (Pfizer Inc.)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Hydrotherapy for the Reversal of Oligohydraminos

Condition: Oligohydramnios
Interventions: Drug: IV/Oral Hydration and Bedrest; Other: Hydrotherapy
Sponsors: Obstetrix Medical Group; Obstetrix Medical Group; Banner Health
Recruiting - verified May 2013
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

Condition: Narcolepsy
Interventions: Drug: ADX-N05; Drug: Placebo
Sponsors: Aerial BioPharma, LLC; Aerial BioPharma, LLC
Recruiting - verified May 2013
A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: JNJ-38518168 (3 mg); Drug: JNJ-38518168 (10 mg); Drug: JNJ-38518168 (30 mg)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266 AM1)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin/Simvastatin FDC; Drug: Sitagliptin; Drug: Simvastatin; Drug: Placebo to sitagliptin; Drug: Placebo to simvastatin; Drug: Placebo to Sitagliptin/Simvastatin FDC; Drug: Metformin; Drug: Glimepiride
Sponsors: Merck; Merck
Recruiting - verified May 2013
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Condition: Alzheimer's Disease
Interventions: Drug: BIIB037; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified May 2013
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/liraglutide; Drug: liraglutide; Drug: exenatide
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Condition: Atrial Fibrillation
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Vitamin K antagonist (VKA)
Sponsors: Bayer; Bayer; Janssen Research & Development, LLC
Recruiting - verified April 2013
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

Condition: Bipolar 1 Disorder
Interventions: Drug: ELND005; Drug: Lamotrigine; Drug: Valproic acid; Drug: Placebo
Sponsors: Elan Pharmaceuticals; Elan Pharma International Limited; Elan Pharmaceuticals
Recruiting - verified May 2013
An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

Condition: Ischemic Dilated Cardiomyopathy (IDCM)
Interventions: Biological: ixmyelocel-T; Other: Vehicle Control
Sponsors: Aastrom Biosciences; Aastrom Biosciences
Recruiting - verified May 2013
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: BI 695500; Drug: BI 695500; Drug: rituximab; Drug: rituximab; Drug: rituximab
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Drug: pegylated liposomal doxorubicin (PLD); Drug: VTX-2337; Drug: Placebo
Sponsors: VentiRx Pharmaceuticals Inc.; VentiRx Pharmaceuticals Inc.; Gynecologic Oncology Group
Recruiting - verified April 2013
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Bevacizumab [Avastin]; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of LY2228820 for Recurrent Ovarian Cancer

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Drug: LY2228820; Drug: Carboplatin; Drug: Placebo; Drug: Gemcitabine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: SAR339658; Other: Placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)

Condition: Brain Metastases From Non-small Cell Lung Cancer
Interventions: Drug: Veliparib; Drug: Veliparib; Drug: Placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

Condition: Infusion Reactions
Intervention: Drug: unlicensed cord blood units
Sponsors: New York Blood Center; New York Blood Center
Recruiting - verified May 2013
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

Conditions: Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Neurofibrosarcoma; Chondrosarcoma; Endometrial Stromal Sarcoma; Mast Cell Sarcoma; Metastatic Adult Malignant Fibrous Histiocytoma of Bone; Ovarian Carcinosarcoma; Ovarian Sarcoma; Recurrent Adult Malignant Fibrous Histiocytoma of Bone; Recurrent Adult Soft Tissue Sarcoma; Small Intestine Leiomyosarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)

Condition: Epilepsy
Intervention: Drug: Brivaracetam
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified April 2013
Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy

Condition: Lumbosacral Radiculopathy
Interventions: Drug: z160; Drug: Placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified May 2013
The Performance of the APPY1 Test in the Evaluation of Possible Acute Appendicitis

Condition: Acute Appendicitis
Intervention:
Sponsors: Venaxis, Inc.; Venaxis, Inc.
Recruiting - verified May 2013
Proof of Biological Activity of SAR100842 in Systemic Sclerosis

Condition: Systemic Sclerosis
Interventions: Drug: SAR100842; Drug: Placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma

Condition: Carcinoma, Renal Cell
Intervention: Drug: Pazopanib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

Condition: Systemic Lupus Erythematosus
Interventions: Drug: belimumab 10mg/kg; Other: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company
Recruiting - verified April 2013
Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer

Conditions: Cervical Cancer; Lymphedema; Sexuality and Reproductive Issues
Interventions: Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cone biopsy; Procedure: genitourinary surgical procedure; Procedure: loop electrosurgical excision procedure; Procedure: quality-of-life assessment; Procedure: therapeutic laparoscopic surgery; Procedure: therapeutic lymphadenectomy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
A Prospective, Randomized, Double-Blind Multicenter Study Comparing Continuous Diffusion of Oxygen (CDO) Therapy to Standard Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcer
Interventions: Device: CDO electrochemical tissue oxygenation system; Device: Moist Wound Therapy
Sponsors: Electrochemical Oxygen Concepts, Inc.; Electrochemical Oxygen Concepts, Inc.
Recruiting - verified May 2013
Efficacy and Safety of SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)

Condition: Hypercholesterolemia
Interventions: Drug: SAR236553 (REGN727); Drug: matching placebo SAR236553 (REGN727); Drug: Ezetimibe; Drug: matching placebo for Ezetimibe
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Condition: Cystic Fibrosis
Interventions: Drug: Aztreonam for Inhalation Solution (AZLI); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified July 2012
Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

Condition: Lupus Nephritis
Interventions: Biological: Placebo plus standard therapy; Biological: Belimumab 10 mg/kg plus standard therapy; Drug: Standard therapy
Sponsors: GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; GlaxoSmithKline
Recruiting - verified December 2012
Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

Condition: Squamous Cell Non-small Cell Lung Cancer
Interventions: Biological: BMS-936558; Drug: Docetaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

Condition: Infections
Interventions: Drug: Ceftaroline fosamil; Drug: Ceftriaxone plus vancomycin
Sponsors: Cerexa, Inc.; Cerexa, Inc.; AstraZeneca
Recruiting - verified May 2013
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Condition: Rheumatoid Arthritis
Interventions: Biological: Rituximab-Pfizer (PF-05280586) x 3 courses; Biological: Rituximab-EU+ Rituximab-Pfizer x 2 Courses; Biological: Rituximab-US + Rituximab-Pfizer x 2 Courses
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012 AM2)

Condition: Asthma
Interventions: Drug: MK-1029 10 mg; Drug: MK-1029 30 mg; Drug: MK-1029 150 mg; Drug: Montelukast 10 mg; Drug: Placebo; Drug: MK-1029 1 mg or 3 mg; Drug: Montelukast 10 mg + MK-1029
Sponsors: Merck; Merck
Recruiting - verified May 2013
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Condition: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Drug: fingolimod; Drug: copaxone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Condition: Polycythemia Vera
Interventions: Drug: ruxolitinib and HU-placebo; Drug: HU and ruxolitinib-placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013
Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis

Condition: Perennial Allergic Rhinitis (PAR)
Intervention: Drug: Beclomethasone Dipropionate (BDP) Nasal Aerosol
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; United BioSource Corporation
Recruiting - verified April 2013
An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis

Conditions: Primary Myelofibrosis; Post Polycythemia Vera Fibrosis; Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: INCB039110
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Custirsen + Docetaxel; Drug: Docetaxel
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
National Parkinson Foundation Quality Improvement Initiative

Condition: Parkinson's Disease
Intervention:
Sponsors: National Parkinson Foundation; National Parkinson Foundation
Recruiting - verified May 2013
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)

Condition: Asthma
Intervention: Device: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)
Sponsors: American Lung Association Asthma Clinical Research Centers; American Lung Association Asthma Clinical Research Centers; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients

Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Drug: Fingolimod; Drug: Placebo Comparator
Sponsors: Novartis; Novartis Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified May 2013
Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011 AM2)

Condition: Asthma
Interventions: Drug: MK-1029; Drug: placebo; Drug: montelukast (ML)
Sponsors: Merck; Merck
Recruiting - verified May 2013
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: Priorix®; Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™); Biological: Kinrix®; Biological: Varivax®
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

Condition: Osteoarthritis of the Knee
Interventions: Drug: NKTR-181; Drug: Placebo
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified May 2013
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

Condition: Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
Intervention: Biological: Darbepoetin alfa
Sponsors: Amgen; Amgen
Recruiting - verified April 2013
Clinical Study of WT2725 in Patients With Advanced Solid Malignancies

Condition: Cancer
Intervention: Biological: WT2725
Sponsors: Sunovion; Sunovion; Dainippon Sumitomo Pharma
Recruiting - verified April 2013
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Condition: Cystic Fibrosis
Interventions: Drug: Ivacaftor; Drug: Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis Foundation
Recruiting - verified April 2013
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND)

Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Study to Determine the Efficacy and Safety of AMG 785 in the Treatment of Postmenopausal Women With Osteoporosis

Condition: Postmenopausal Women With Osteoporosis
Interventions: Drug: AMG 785; Drug: Alendronate
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified May 2013
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND)

Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease

Condition: Alzheimer Disease
Interventions: Device: DBS-f on; Device: DBS-f off
Sponsors: Functional Neuromodulation Ltd; Functional Neuromodulation Ltd
Recruiting - verified May 2013
Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder

Condition: Female Orgasmic Disorder
Interventions: Drug: Placebo; Drug: Low dose TBS-2; Drug: Medium dose TBS-2; Drug: High dose TBS-2
Sponsors: Trimel Biopharma SRL; Trimel Biopharma SRL
Recruiting - verified May 2013
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Compare Ceftazidime-Avibactam and Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Conditions: cUTI; Complicated Urinary Tract Infection; Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem; Drug: Either switch to oral therapy : 500 mg of Ciprofloxacin (oral); Drug: or switch to oral therapy : 800 mg/160 mg of sulfamethoxazole/trimethoprim
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified May 2013
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

Condition: Diabetic Nephropathy
Interventions: Drug: Repository Corticotropin Injection; Drug: Placebo
Sponsors: Questcor Pharmaceuticals, Inc.; Questcor Pharmaceuticals, Inc.
Recruiting - verified May 2013
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib; Drug: Bendamustine hydrochloride; Drug: Rituximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo; Drug: Fulvestrant; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab Dosing Regimen; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Condition: Melanoma
Interventions: Drug: Dabrafenib; Drug: Vemurafenib; Drug: Trametinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies

Conditions: Aneuploidy; Down Syndrome; Noninvasive Prenatal Screening
Intervention: Device: SEQureDx Trisomy Test
Sponsors: Sequenom, Inc.; Sequenom, Inc.
Recruiting - verified May 2013
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Conditions: Autism Spectrum Disorder (ASD); Autism; Autistic Disorder; Asperger's Disorder; Asperger's; Pediatric Autism; Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS); Pervasive Child Development Disorder
Intervention: Drug: Memantine Hydrochloride (HCl)
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified April 2013
Bioness® StimRouter™ Neuromodulation System for Chronic Pain Therapy

Condition: Chronic Pain
Interventions: Device: SR-electrical stimulation (Bioness); Device: Control ES and pain medication during first 3 months (Bioness)
Sponsors: Bioness Inc; Bioness Inc
Recruiting - verified April 2013
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

Condition: Hypercholesterolemia
Interventions: Drug: PBO; Drug: 200mg PF-04950615 (RN316); Drug: 300mg PF-04950615 (RN316); Drug: PBO; Drug: PF-04950615; Drug: PF-04950615; Drug: PF-04950615
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Condition: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem; Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral); Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified May 2013
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

Condition: Anaemia
Interventions: Drug: GSK1278863; Drug: rhEPO
Sponsors: GlaxoSmithKline; GlaxoSmithKline; PPD
Recruiting - verified May 2013
International Guillain-Barré Syndrome Outcome Study

Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome
Intervention:
Sponsors: Erasmus Medical Center; Erasmus Medical Center
Recruiting - verified May 2013
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

Condition: Age-Related Maculopathy
Interventions: Biological: RN6G; Biological: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: BKM120 matching placebo; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

Conditions: Chronic Pain; Low Back Pain; Analgesia
Interventions: Drug: ALO-02; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
CentriMag RVAS U.S. Post-approval Study Protocol

Condition: Right Ventricular Failure
Intervention: Device: CentriMag RVAS placement
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

Condition: Hemophilia A
Intervention: Biological: BAY94-9027
Sponsors: Bayer; Bayer
Recruiting - verified April 2013
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: vinorelbine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Non-Drug Study of The Suitability of Neurocognitive Tests And Functioning Scales For The Measurement of Cognitive And Functioning Changes in Individuals With Down Syndrome

Condition: Down Syndrome
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: LY2886721; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 16 Years With Bladder Overactivity Caused By A Neurological Condition

Condition: Urinary Bladder, Neurogenic
Interventions: Drug: Fesoterodine 4 mg; Drug: Fesoterodine 8 mg; Drug: Oxybutynin; Drug: Fesoterodine
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcers
Interventions: Other: Tissue; Other: Control
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Recruiting - verified May 2013
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

Condition: Unresectable Hepatocellular Carcinoma
Intervention: Device: TheraSphere
Sponsors: Nordion (Canada) Inc.; Nordion (Canada) Inc.
Recruiting - verified May 2013
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Other: Placebo Comparator
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Drug: Placebo
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013
A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders

Conditions: Parkinson's Disease; Primary Parkinsonism; Lewy Body Parkinson's Disease
Intervention: Drug: 18F-AV-133
Sponsors: Avid Radiopharmaceuticals; Avid Radiopharmaceuticals
Recruiting - verified May 2013
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM2)

Condition: Hepatitis C, Chronic
Interventions: Biological: peginterferon alfa-2a; Drug: ribavirin; Drug: boceprevir
Sponsors: Merck; Merck
Recruiting - verified May 2013
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: rifaximin; Drug: placebo
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified January 2013
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies

Conditions: Down Syndrome; Fetal Aneuploidy
Intervention:
Sponsors: Sequenom, Inc.; Sequenom, Inc.
Recruiting - verified May 2013
Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

Condition: Advanced Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Phase 1/2, Open-label, Dose-escalation Study of ISIS-STAT3Rx, Administered to Patients With Advanced Cancers

Conditions: Advanced Cancers; DLBCL; Lymphoma
Intervention: Drug: ISIS-STAT3Rx
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals; AstraZeneca
Recruiting - verified April 2013
Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Conditions: Neovascular Age-elated Macular Degeneration (Wet AMD); Exudative Macular Degeneration
Interventions: Drug: LFG316; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

Conditions: Geographic Atrophy; Age-related Macular Degeneration
Interventions: Drug: LFG316; Drug: Sham
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Condition: Rheumatoid Arthritis
Interventions: Biological: PF-05280586; Biological: MabThera; Biological: Rituxan
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: afatinib; Drug: erlotinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Conditions: Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Secondary Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Condition: Multiple Myeloma, Neoplasms
Intervention: Drug: Vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified May 2013
A Study of RO4917523 in Patients With Fragile X Syndrome

Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified April 2013
Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Condition: Psoriasis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: mitoxantrone; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified May 2013
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

Condition: Tophaceous Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013
Combining Lesinurad With Allopurinol in Inadequate Responders

Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

Conditions: Chronic Myocardial Ischemia; Refractory Angina Pectoris; (Advanced) Coronary Heart Disease
Interventions: Biological: Auto-CD34+ cells; Biological: Placebo: Diluent used to suspend Auto-CD34+ cells; Other: Standard of care
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified May 2013
Long-term Safety and Tolerability of SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Condition: Hypercholesterolemia
Interventions: Other: placebo; Drug: SAR236553 (REGN727)
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

Conditions: Diffuse Large B-cell Lymphoma; Follicle Center Lymphoma
Intervention: Drug: Zevalin (ibritumomab tiuxetan)
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013
Maintenance Plasma Exchange for Neuromyelitis Optica

Conditions: Neuromyelitis Optica; Neuromyelitis Optica Spectrum Disorder; Recurrent Idiopathic Longitudinally Extensive Transverse Myelitis
Intervention: Procedure: Plasma exchange (PLEX)
Sponsors: Mayo Clinic; Mayo Clinic; Terumo BCT
Recruiting - verified April 2013
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (CZP + MTX); Biological: Adalimumab + Methotrexate (ADA + MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified May 2013
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
Interventions: Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections

Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified May 2013
Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: MM-398; Drug: 5 Fluorouracil; Drug: Leucovorin
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified April 2013
Combining Lesinurad With Allopurinol in Inadequate Responders

Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Condition: Irritable Bowel Syndrome
Interventions: Drug: 250 mg LX1033 tablets; Drug: Placebo tablet
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified April 2013
AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

Condition: ST Segment Elevation Myocardial Infarction
Interventions: Biological: AMR-001; Other: placebo
Sponsors: Amorcyte, Inc.; Amorcyte, Inc.
Recruiting - verified February 2013
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A

Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified April 2013
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Condition: Relapsed or Refractory Solid Tumors
Interventions: Drug: CC-486 plus Carboplatin; Drug: CC-486 plus ABI-007; Drug: CC-486
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

Condition: Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: nab-paclitaxel; Drug: FOLFIRINOX; Genetic: Immunohistochemistry (IHC) Analysis; Drug: Metformin
Sponsors: Pancreatic Cancer Research Team; Pancreatic Cancer Research Team
Recruiting - verified September 2012
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: Pregabalin; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)

Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Merck; Merck
Recruiting - verified May 2013
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Condition: Ovarian Cancer, Pancreatic Cancer
Intervention: Drug: DMOT4039A
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

Conditions: Chronic Kidney Disease; Chronic Renal Failure
Interventions: Biological: Epoetin Hospira; Biological: Epogen (Amgen)
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified May 2013
GLORIA-AF Registry Program - Second and Third Phases

Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain

Condition: Neuropathic Pain
Interventions: Drug: SAR292833; Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study Of Oral CP-690550 As A Maintenance Therapy For Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: Placebo; Drug: CP690,550; Drug: CP690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment

Condition: Depression Disorder, Major
Interventions: Drug: RO4995819; Drug: RO4995819; Drug: RO4995819; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

Conditions: Multiple Myeloma; Solid Tumors; Non-Small Cell Lung Cancer
Intervention: Drug: DKN-01
Sponsors: Dekkun Corporation; Dekkun Corporation
Recruiting - verified May 2013
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Condition: Spasticity
Interventions: Drug: Baclofen ER Capsules; Drug: Placebo GRS
Sponsors: Sun Pharma Advanced Research Company Limited; Sun Pharma Advanced Research Company Limited
Recruiting - verified April 2013
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Condition: Epilepsy, Partial Seizures
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Condition: Paroxysmal Atrial Fibrillation
Interventions: Device: EAS-AC (HeartLight); Procedure: Control Arm Ablation
Sponsors: CardioFocus; CardioFocus
Recruiting - verified April 2013
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension
Interventions: Drug: Nitric Oxide; Other: Placebo; Drug: Nitric Oxide
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013
Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)

Condition: Pulmonary Emphysema
Interventions: Device: Treatment plus Optimal Medical Therapy; Other: Optimal Medical Therapy
Sponsors: Aeris Therapeutics; Aeris Therapeutics
Recruiting - verified May 2013
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Conditions: Inoperable Locally Advanced Breast Cancer; Metastatic Breast Cancer (MBC)
Intervention: Drug: BEZ235 + Paclitaxel
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 + MCV4 + Tdap; Biological: MCV4 + Tdap + saline; Biological: rLP2086 + saline
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 and Gardasil; Biological: rLP2086; Biological: Gardasil
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

Conditions: Coronary Artery Disease; Angina Pectoris
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Open Label Study of Long Term Evaluation Against LDL-C Trial

Condition: Hypercholesterolemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified April 2013
A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery

Conditions: Keratoconus; Corneal Ectasia
Interventions: Device: KXL System (15 mW/cm2); Device: KXL System (30 mW/cm2); Device: KXL System (45 mW/cm2); Drug: riboflavin ophthalmic solution
Sponsors: ACOS; ACOS
Recruiting - verified May 2013
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Condition: Thrombocytopaenia
Interventions: Drug: eltrombopag; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression

Condition: Fibromyalgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

Condition: Hepatorenal Syndrome
Interventions: Drug: 5mg Ifetroban Injection; Drug: 15mg Ifetroban Injection; Drug: 50mg Ifetroban Injection; Drug: 150mg Ifetroban Injection; Other: 5% Dextrose in Water
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified April 2013
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

Condition: Asthma
Interventions: Drug: Placebo; Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified April 2013
A Study of RG1662 in Individuals With Down Syndrome

Condition: Down Syndrome
Interventions: Drug: RG1662; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine [Kadcyla]; Drug: anti-cancer therapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
VA Augmentation and Switching Treatments for Improving Depression Outcomes

Condition: Major Depressive Disorder
Interventions: Drug: Augmenting: Antidepressant + Aripiprazole; Drug: Augmenting: Antidepressant + Bupropion-SR; Drug: Switching: Bupropion-SR
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2013
Blood Tests to Study Injury Severity and Outcome in Traumatic Brain Injury Patients

Condition: Traumatic Brain Injury
Intervention:
Sponsors: Emory University; Emory University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

Conditions: Alzheimer Disease; Mild Cognitive Impairment; Neurodegenerative Diseases
Intervention: Drug: Florbetapir F 18
Sponsors: Avid Radiopharmaceuticals; Avid Radiopharmaceuticals
Recruiting - verified May 2013
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

Conditions: Colorectal Carcinoma; CRC
Interventions: Biological: JX-594; Drug: Irinotecan
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics; Transgene
Recruiting - verified January 2012
Hydrogel Endovascular Aneurysm Treatment Trial

Condition: Cerebral Aneurysm
Interventions: Device: HydroCoil Embolic System; Device: Control (bare platinum coils)
Sponsors: Northwestern University; Northwestern University; MicroVention, Inc
Recruiting - verified May 2013
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years

Condition: Epilepsy, Partial Seizures
Interventions: Drug: Pregabalin add-on therapy; Drug: Pregabalin add-on therapy; Drug: Pregabalin add-on therapy
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified May 2013
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer

Condition: Neoplasms
Interventions: Drug: BAY80-6946 + BAY86-9766; Drug: BAY80-6946 + BAY86-9766
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: prednisone; Other: prednisone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013
A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement

Condition: Muscular Atrophy
Interventions: Drug: LY2495655; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013
A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adults With Myelofibrosis

Condition: Myelofibrosis
Interventions: Drug: GS-6624 at 700 mg; Drug: GS-6624 at 200 mg
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

Conditions: Acute Ischemic Stroke; Diabetes; Hyperglycemia
Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Sponsors: University of Virginia; University of Virginia; Neurological Emergencies Treatment Trials Network (NETT); Medical University of South Carolina; Medical Automation Systems, an Alere Company; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified April 2013
Dystonia Coalition Projects

Conditions: Dystonia; Voice Disorders
Intervention:
Sponsors: Emory University; Hyder A. Jinnah, MD, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Office of Rare Diseases (ORD); Allergan; Dystonia Study Group
Recruiting - verified May 2013
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Condition: Endometrial Cancer
Interventions: Drug: Carboplatin/Paclitaxel; Drug: Trastuzumab
Sponsors: Yale University; Yale University; Genentech
Recruiting - verified May 2013
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified May 2013
A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001 AM4)

Condition: Tumor, Solid
Intervention: Drug: MK-8353
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age

Conditions: Acute Myeloid Leukemia; Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine-single agent; Drug: Lenalidomide - single agent; Drug: Lenalidomide in combination with azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Condition: Meningitis, Meningococcal
Interventions: Biological: rLP2086 vaccine; Biological: control
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2013
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2013
S0820, Adenoma and Second Primary Prevention Trial

Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo; Drug: eflornithine & sulindac placebo; Drug: Eflornithine placebo & sulindac; Drug: Eflornithine plus sulindac
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.
Recruiting - verified May 2013
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02; Other: Standard of Care
Sponsors: Dendreon; Dendreon
Recruiting - verified April 2013
B0151003 Open-Label Extension Study

Condition: Crohn's Disease
Interventions: Biological: PF-04236921; Biological: PF-04236921
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Conditions: Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab; Drug: Zoledronic acid
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2013
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2013
Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Condition: Atrophy, Geographic
Interventions: Drug: GSK933776; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2013
Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: placebo; Drug: BI1356 low dose; Drug: BI1356 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013
A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: etanercept
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Condition: Carotid Stenosis
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsors: Bayer; Bayer
Recruiting - verified April 2013
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Furoate/Vilanterol; Drug: Vilanterol; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Conditions: Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab; Drug: Gemcitabine + Rituximab
Sponsors: Cell Therapeutics; Cell Therapeutics
Recruiting - verified April 2013
Smoking Cessation Study In Healthy Adolescent Smokers

Condition: Smoking Cessation
Interventions: Drug: Varenicline 1mg BID; Drug: Varenicline 0.5mg BID; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified April 2013
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: Placebo; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Open-Label Extension Study of GSK1605786A

Condition: Crohn's Disease
Intervention: Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

Conditions: Graft Versus Host Disease; Systemic Scleroderma
Interventions: Drug: imatinib mesylate; Biological: rituximab; Other: questionnaire administration; Procedure: biopsy; Other: cytology specimen collection procedure
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2013
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2013
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Condition: Warfarin Therapy
Intervention: Device: Warfarin GenoSTAT Test
Sponsors: Iverson Genetic Diagnostics, Inc.; Iverson Genetic Diagnostics, Inc.
Recruiting - verified April 2013
INcrease Of VAgal TonE in CHF

Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013
Internet-Based Sexual Health Education for Middle School Native American Youth

Conditions: Sexually Transmitted Diseases; Pregnancy; HIV Infections
Interventions: Behavioral: HIV, STI and Pregnancy Prevention Curriculum; Behavioral: Control Curricula
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; Alaska Native Tribal Health Consortium; Inter Tribal Council of Arizona; Northwest Portland Area Indian Health Board
Recruiting - verified May 2013
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Conditions: Metastatic Cancer; Cancer; Solid Tumors
Intervention: Drug: BIND-014
Sponsors: BIND Therapeutics; BIND Therapeutics
Recruiting - verified April 2013
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Condition: Cancer, Solid Tumor
Interventions: Drug: lambrolizumab 1 mg/kg; Drug: lambrolizumab 3 mg/kg; Drug: lambrolizumab 10 mg/kg; Drug: lambrolizumab MEL; Drug: lambrolizumab NSCLC; Drug: lambrolizumab MEL Low Dose; Drug: lambrolizumab MEL High Dose; Drug: lambrolizumab NSCLC Low Dose; Drug: lambrolizumab NSCLC High Dose; Drug: lambrolizumab NSCLC Medium Dose
Sponsors: Merck; Merck
Recruiting - verified May 2013
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

Conditions: Solid Tumors; Relapsed/Refractory Sarcomas
Intervention: Drug: Vorinostat and Etoposide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck; Phoenix Children's Hospital; Milton S. Hershey Medical Center; Johns Hopkins University; Sidney Kimmel Comprehensive Cancer Center; Children's Hospital Colorado; University of Florida; Alberta Children's Hospital; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Children's Mercy Hospital & Clinics; All Children's Hospital; Arnold Palmer Hospital for Children/MD Anderson Cancer Center Orlando
Recruiting - verified May 2013
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Condition: Crohn's Disease
Interventions: Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Condition: Lymphoma, B-Cell
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: CHOP chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Fondazione Italiana Linfomi ONLUS
Recruiting - verified May 2013
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Conditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: docetaxel; Drug: cyclophosphamide; Biological: trastuzumab; Drug: paclitaxel; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Conditions: Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b; Other: pharmacological study; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

Condition: Post Herpetic Neuralgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Treprostinil
Sponsors: Los Angeles Biomedical Research Institute; Los Angeles Biomedical Research Institute; United Therapeutics
Recruiting - verified April 2013
Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

Condition: Epilepsy
Interventions: Drug: Placebo; Drug: Brivaracetam; Drug: Brivaracetam
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013
Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol for oral suspension placebo proxy; Drug: Welchol for oral suspension
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified May 2013
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

Conditions: Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Biological: cetuximab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)

Condition: Critical Limb Ischemia
Interventions: Device: BMAC injection; Device: Placebo injection
Sponsors: Harvest Technologies; Harvest Technologies
Recruiting - verified April 2013
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

Conditions: Epilepsy; Monotherapy
Interventions: Drug: Lacosamide; Drug: Carbamazepine-Controlled Release
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH; EDEV S.À.R.L
Recruiting - verified May 2013
Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Procedure: therapeutic dietary intervention
Sponsors: Alliance for Clinical Oncology Trials; Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2013
A Study to Test Safety and Efficacy of IMGN901 in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

Condition: Small Cell Lung Cancer
Interventions: Drug: IMGN901; Drug: Carboplatin and Etoposide
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified April 2013
A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome

Condition: Fibromyalgia
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Bosutinib For Autosomal Dominant Polycystic Kidney Disease

Condition: Polycystic Kidney, Autosomal Dominant
Interventions: Drug: Bosutinib; Drug: Bosutinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Alzheimer's Disease Neuroimaging Initiative 2

Conditions: Mild Cognitive Impairment (MCI); Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified May 2013
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212; Drug: Other approved anti-cancer agent
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study in Advanced Cancer

Condition: Advanced Cancer
Intervention: Drug: LY2940680
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease

Condition: Alzheimer Disease
Interventions: Drug: gantenerumab; Drug: gantenerumab; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2013
Post-Myocardial Infarction Remodeling Prevention Therapy

Conditions: Acute Myocardial Infarction; Pacing Therapy; Cardiac Remodeling; Heart Failure
Interventions: Device: Single Site Pacing; Device: Dual Site Pacing
Sponsors: Medtronic Cardiac Rhythm Disease Management; Medtronic Cardiac Rhythm Disease Management
Recruiting - verified May 2013
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108 AM1)

Condition: Spondylitis, Ankylosing
Interventions: Drug: Part I - etoricoxib 60 mg; Drug: Part I - etoricoxib 90 mg; Drug: Part I- naproxen 1000 mg; Drug: Part I - Placebo to naproxen 500 mg; Drug: Part II- etoricoxib 60 mg; Drug: Part II- etoricoxib 90 mg; Drug: Part II- naproxen 1000 mg
Sponsors: Merck; Merck
Recruiting - verified May 2013
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

Conditions: Graft vs Host Disease; Cutaneous Sclerosis; Bronchiolitis Obliterans
Intervention:
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified April 2013
A Study of LY2127399 in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study of LY2127399 in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: ocrelizumab; Drug: Placebo; Drug: methylprednisolone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study in Second Line Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2013
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
Interventions: Other: clinical observation; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)

Condition: Contrast Induced Nephropathy
Interventions: Device: CINCOR™ System; Drug: Peri-procedural hydration
Sponsors: Osprey Medical, Inc; Osprey Medical, Inc
Recruiting - verified April 2013
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Gilead Sciences
Recruiting - verified May 2013
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab); Drug: Pemetrexed; Drug: Carboplatin (AUC 6); Drug: Cisplatin; Drug: Gemcitabine; Drug: Carboplatin (AUC 5)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified March 2013
Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

Condition: Bladder Cancer Requiring Cystectomy
Interventions: Other: Quality of Life Questionnaires; Other: Get up and Go test; Other: Hand Grip test
Sponsors: University of Miami; University of Miami; National Cancer Institute (NCI)
Recruiting - verified April 2013
Excision Followed by Radiofrequency Ablation for Breast Cancer

Condition: Breast Cancer
Intervention: Device: Radiofrequency Ablation
Sponsors: University of Arkansas; University of Arkansas; Angiodynamics, Inc.
Recruiting - verified April 2013
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

Condition: Thrombocytopaenia
Interventions: Drug: Eltrombopag olamine; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
A Study in Patients With Diabetic Kidney Disease

Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Condition: Peripheral T-cell Lymphoma
Intervention:
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Selexipag (ACT-293987); Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2013
Dose Escalation Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Condition: Hematological Malignancy
Intervention: Drug: SAR650984
Sponsors: Sanofi; Sanofi
Recruiting - verified April 2013
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen

Condition: Lymphoma, Follicular
Interventions: Drug: Ofatumumab and Bendamustine infusions (Arm A); Drug: Bendamustine infusion (Arm B)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified April 2013
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Other: Observation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

Condition: Thymic Carcinoma
Intervention: Drug: Milciclib Maleate
Sponsors: Nerviano Medical Sciences; Nerviano Medical Sciences
Recruiting - verified May 2013
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Condition: Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Condition: Neoplasms
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

Condition: Alzheimer Disease
Intervention: Drug: ACC-001+ QS21
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified May 2013
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013
Studying Biomarkers in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

Conditions: Atypical Endocervical Glandular Cell of Undetermined Significance; Atypical Endometrial Hyperplasia; Atypical Glandular Cell of Undetermined Significance; Cervical Cancer; Cervical Intraepithelial Neoplasia Grade 2; Cervical Intraepithelial Neoplasia Grade 3; Human Papilloma Virus Infection
Intervention: Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: NKTR-102; Drug: irinotecan
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2013
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure

Condition: Chronic Heart Failure
Interventions: Drug: Enalapril monotherapy; Drug: Aliskiren monotherapy; Drug: Aliskiren / Enalapril combination therapy
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
Atorvastatin Three Year Pediatric Study

Condition: Familial Hypercholesterolemia
Intervention: Drug: atorvastatin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Progesterone for the Treatment of Traumatic Brain Injury

Condition: Traumatic Brain Injury
Intervention: Drug: Progesterone
Sponsors: Emory University; David Wright
Recruiting - verified May 2013
CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass

Condition: Heart Failure
Intervention: Device: CentriMag Ventricular Assist System
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Conditions: Multiple Myeloma; Plasma Cell Neoplasm
Interventions: Drug: Group A=30-60 CrCl (mL/min); Drug: Group B=CrCL<30 mL/min not on dialysis; Drug: Group C=CrCL<30 mL/min and on dialysis
Sponsors: PrECOG, LLC.; PrECOG, LLC.; Celgene Corporation
Recruiting - verified May 2013
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Condition: Human Immunodeficiency Virus (HIV)
Intervention: Drug: Maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013
Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

Conditions: Non-small Cell Lung Cancer; Squamous Lung Dysplasia
Interventions: Drug: inositol; Other: placebo
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
AngelMed for Early Recognition and Treatment of STEMI

Conditions: Acute Myocardial Infarction (AMI); Coronary Occlusion; Acute Coronary Syndrome
Intervention: Device: AngelMed Guardian System
Sponsors: Angel Medical Systems; Angel Medical Systems; Symbios Clinical
Recruiting - verified May 2013
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); BSN Medical Inc; Genentech; Covidien; BayerHealthcare; Mid America Heart Institute; Society of Interventional Radiology Foundation; Massachusetts General Hospital
Recruiting - verified May 2013
Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"

Condition: Methicillin-Resistant S.Aureus
Interventions: Drug: Placebo; Drug: Trimethoprim-sulfamethoxazole (TS); Drug: Cephalexin; Drug: Clindamycin
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2012
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

Conditions: Psychotic Depression; Major Depression With Psychotic Features; Psychosis
Interventions: Drug: mifepristone; Drug: placebo
Sponsors: Corcept Therapeutics; Corcept Therapeutics
Recruiting - verified April 2013
A Safety and Efficacy Study of the Birmingham Hip Resurfacing System

Condition: Arthritis
Intervention: Device: Birmingham Hip Resurfacing
Sponsors: Smith & Nephew, Inc.; Smith & Nephew, Inc.
Recruiting - verified May 2013
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Conditions: Crohn's Disease; Ulcerative Colitis; Indeterminate Colitis; Inflammatory Bowel Diseases
Interventions: Biological: Anti TNF therapy including infliximab; Drug: No Biologics
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: melphalan; Drug: prednisone; Drug: thalidomide; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Condition of Approval Study

Condition: Lumbar Spinal Stenosis
Intervention: Device: X-STOP PEEK
Sponsors: Medtronic Spine LLC; Medtronic Spine LLC
Recruiting - verified April 2013
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Recruiting - verified May 2013
Evaluating the Role of Thrombin in Saphenous Vein Graft Failure After Heart Bypass Surgery

Conditions: Coronary Artery Bypass; Thrombosis
Intervention:
Sponsors: University of Arizona; University of Arizona; University of Maryland, Baltimore County
Recruiting - verified May 2013
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: adult human mesenchymal stem cells; Drug: Placebo
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Recruiting - verified May 2013
Study of the Safety and Effectiveness of DIAM™ Spinal Stabilization System Versus Conservative Care

Condition: Lumbar Degenerative Disc Disease
Interventions: Device: DIAM™ Spinal Stabilization System; Procedure: Conservative care
Sponsors: Medtronic Spinal and Biologics; Medtronic Spinal and Biologics
Recruiting - verified April 2013
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures

Condition: Epilepsies, Partial
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2013
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer
Interventions: Drug: cisplatin; Drug: tirapazamine
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); NCIC Clinical Trials Group
Recruiting - verified May 2013
Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI); CTI
Recruiting - verified May 2013
Emergency Use Program for HTE HIV+ Patients Who Need Tipranavir Treatment

Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2013

Find Paid Research Studies in Avondale,Arizona

Welcome to Paid Research Studies.